Literature DB >> 14715310

Detection of wild type and deleted latent membrane protein 1 (LMP1) of Epstein-Barr virus in clinical biopsy material.

John Nicholls1, Peter Hahn, Elisabeth Kremmer, Thomas Fröhlich, Georg J Arnold, Jonathan Sham, Dora Kwong, Friedrich A Grässer.   

Abstract

The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is one of two postulated viral oncogenic proteins. Sequence variations, and in particular a 30 base pair deletion variant called CAO, may define different disease populations. We developed a panel of rat monoclonal antibodies (MAb) specific for the non-wild type LMP1 and compared the presence of the antibody staining with LMP1 DNA sequence analysis on clinical samples of nasopharyngeal carcinoma, peripheral T-cell lymphoma (PTCL), Hodgkin's disease, lymphoblastoid cell lines (LCL) from normal volunteers, and patients with nasopharyngeal carcinoma. The results demonstrate specificity of the monoclonal cocktail for detecting the non-wild type LMP1 and the ability to sub-differentiate between the mediterranean type of LMP1 and the CAO-LMP1. Double immunofluorescence on paraffin material using the traditional CS1-4 monoclonal antibodies and the CAO-cocktail revealed no dual population of cells in the biopsy material from the Asian region.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715310     DOI: 10.1016/j.jviromet.2003.10.015

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  6 in total

1.  Evaluation of LMP1 of Epstein-Barr virus as a therapeutic target by its inhibition.

Authors:  Adele Hannigan; Joanna B Wilson
Journal:  Mol Cancer       Date:  2010-07-09       Impact factor: 27.401

2.  Genetic diversity of EBV-encoded LMP1 in the Swiss HIV Cohort Study and implication for NF-Κb activation.

Authors:  Emilie Zuercher; Christophe Butticaz; Josiane Wyniger; Raquel Martinez; Manuel Battegay; Emmanuelle Boffi El Amari; Thanh Dang; Jean-François Egger; Jan Fehr; Esther Mueller-Garamvögyi; Andrea Parini; Stephan C Schaefer; Franziska Schoeni-Affolter; Christine Thurnheer; Marianne Tinguely; Amalio Telenti; Sylvia Rothenberger
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

3.  Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.

Authors:  Chiara Rancan; Leah Schirrmann; Corinna Hüls; Reinhard Zeidler; Andreas Moosmann
Journal:  PLoS Pathog       Date:  2015-06-11       Impact factor: 6.823

4.  Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.

Authors:  Corey Smith; Victor Lee; Andrea Schuessler; Leone Beagley; Sweera Rehan; Janice Tsang; Vivian Li; Randal Tiu; David Smith; Michelle A Neller; Katherine K Matthews; Emma Gostick; David A Price; Jacqueline Burrows; Glen M Boyle; Daniel Chua; Benedict Panizza; Sandro V Porceddu; John Nicholls; Dora Kwong; Rajiv Khanna
Journal:  Oncoimmunology       Date:  2017-01-04       Impact factor: 8.110

5.  The germinal center kinase TNIK is required for canonical NF-κB and JNK signaling in B-cells by the EBV oncoprotein LMP1 and the CD40 receptor.

Authors:  Anna Shkoda; Jennifer A Town; Janine Griese; Michael Romio; Hakan Sarioglu; Thomas Knöfel; Fabian Giehler; Arnd Kieser
Journal:  PLoS Biol       Date:  2012-08-14       Impact factor: 8.029

6.  A central role of IKK2 and TPL2 in JNK activation and viral B-cell transformation.

Authors:  Stefanie Voigt; Kai R Sterz; Fabian Giehler; Anne-Wiebe Mohr; Joanna B Wilson; Andreas Moosmann; Arnd Kieser
Journal:  Nat Commun       Date:  2020-02-04       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.